key: cord-1004403-zhdrua1e authors: Ibrahimagić, Omer Ć.; Smajlović, Dževdet; Dostović, Zikrija; Vidović, Mirjana; Tupković, Emir; Kunić, Suljo title: COMMENT ON AN ARTICLE: “Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19“ date: 2020-07-15 journal: Med Hypotheses DOI: 10.1016/j.mehy.2020.110107 sha: a7013b4e883c0f493e67634e6e46d4a1178c7256 doc_id: 1004403 cord_uid: zhdrua1e nan We have read with great attention the article "Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19", written by colleagues Ponti, Ruini and Tomasi (Authors) in the forthcoming October issue of Medical Hypotheses, published online in the May issue of same Journal (1). This interesting article evaluates possible relation between hyperhomocysteinemia and cardiovascular risk in patients with COVID-19. We welcome the opportunity to make a short comment as well. Undoubtedly, hyperhomocysteinemia has neurotoxic, neuroinflammatory, neurodegenerative, proatherogenic, prothrombotic, and prooxidative effects (2) . It is linked with the existence of C667T MTHFR mutation, but also with reduced levels of B9 (folic acid) and other B-vitamins (3). In our study, we have shown that almost 17% of patients with prothrombotic / proembolic ischemic stroke had non-iatrogenic hyperhomocysteinemia (4). Furthermore, previous reports unveiled that hyperhomocysteinemia contributed alongside many virus-infections including: human hepatitis virus, human papilloma virus, as well as human immunodeficiency virus (5, 6, 7) . Novelty pandemic coronavirus disease (COVID-19) has yet unclear kaleidoscopic presentation. Also, (co)incidental appearance of hyperhomocysteinemia can make numerous negative effects, but not only in COVID-19 patients. Unfortunately, there was very poor reliable data of their concomitance according to PubMed survey. Later, follow-up imaging in SARS-CoV-2 patients with pneumonia often demonstrated the disease severity (8) . Interestingly, high number of pulmonary embolism was noted in COVID-19 pneumonia patients (20.6%), despite the fact that 90% of them were receiving prophylactic antithrombotic treatment according to the current guidelines. So, failure to identify cardiovascular risk could worsen the prognosis (9) . It is of great importance for early warning of aggravation, which could help clinicians manage quickly and accurately (10) . showed predictive value for CT-imaging progressions (1, 11) . Our studies show that the intake of B9 vitamin, sometimes with other vitamins in this group, was effective in creating normalized homocysteine levels in patients with ishemic stroke and Parkinson's disease (4, 3) . Furthermore, other studies also prove its quality in lowering hyperhomocysteinemia (12, 13) . B-vitamins (B2, B3, B6) are identified with the enhancement of the immune system (14) . Consequently, their prescriptions for COVID-19 patients should continue as per usual in clinical practice (15) . We emphasize that B9 vitamin and other B-vitamins are "on the first-line" -good and safe in reduction levels of homocysteine. Therefore, B-vitamins can, ad hoc, become the medication of choice in the treatment when harmful hyperhomocysteinemia coexisting with COVID-19. Finally, we would encourage other professionals on making future efforts, as well as investigations and discussions about this topic. This report received no specific grant from any funding agency in the public, commercial, or not for profit sectors. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19 Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses Hyperhomocysteinemia and its treatment in patients with Parkinson's disease Hyperhomocysteinemia and its treatment in patients with ischemic stroke Stetosis, chronic hepatitis virus C infection and homocysteine Human papilloma virus persistence and neopterin, folate and homocysteine levels in cervical dysplasias Elevated homocysteine in human defficiency virus infected patients under antiretroviral therapy: A meta-analysis CT imaging features of 2019 novel coronavirus (2019-nCoV) Pulmonary embolism in COVID-19 patients: Awareness of an increased prevalence Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients Homocysteine, diet and cardiovascular disease: a statement for healtcare professionals from the Nutrition Committee Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients Potential interventions for novel coronavirus in China: a systematic review Medications in COVID-19 patients: summarizing the current literature from an orthopaedic perspective All authors declare that there is no conflict of interest.